With the exception of several pharma companies, 2017 led to a 1.1 percent dip in net prices for the fourth quarter, according to a report by SSR Health, though overall list prices increased 5.5 percent.
Some companies, however, managed to push out solid price gains.
According to a Fierce Pharma report, Celgene’s Revlimid, AbbVie’s Humira, Roche’s Rituxan and Avastin, and Novo Nordisk’s Victoza had the biggest contribution to net price increases.
Gilead’s Epclusa and Harvoni, hepatitis C antiviral medications, posted the largest dip in net prices, per the report.
The report says price increases fueled the majority of Celgene and AbbVie’s sale growth. Revlimid led to Celgen’s 78.6 percent growth during the fourth quarter, while 99.3 percent of AbbVie’s growth was the direct result of Humira’s higher prices.